Guwahati: One of the potential vaccines against COVID-19 by AstraZeneca, the AstraZeneca plcAZN.L (AZN.L) will provide protection against contracting the infectious virus for only a year. This was told by Pascal Soriot, the CEO of the company on Tuesday, June 16.
The British drugmaker has already started the human trials of the vaccine. The vaccine is created by the University of Oxford, with phase I of the trial in Britain to end soon and phase III trial already making its headway as stated by Soriot.
Serum Institute of India (SII) has signed a deal with Astra Zeneca to supply one billion doses of vaccine for low and middle-income countries.
“Serum Institute of India is delighted to partner with Astra Zeneca in bringing this vaccine to India as well as low and middle-income countries. Over the past 50 years, SII has built significant capability in vaccine manufacturing and supply globally. We will work closely with Astra Zeneca to ensure fair and equitable distribution of the vaccine in these countries,” said the company statement.
On Saturday, AstraZeneca also signed contracts with Netherlands, Italy, France, and Germany to supply the entire European Union with up to 400 million doses of the potential vaccine against COVID-19. Additionally, they had already agreed on some deals with Britain and the United States.
“If all goes well, we will have the results of the clinical trials in August/September. We are manufacturing in parallel. We will be ready to deliver from October if all goes well,” Soriot said to a Belgian radio station on Tuesday.
Also Read: COVID-19: When will a vaccine for be ready?
- Students who lost parents to COVID won’t be charged exam fee
- Assam government orders inquiry into Bodoland encounter
- Gandhi, Godse, and ‘Freedom at Midnight’
- These must-have foods help you have a happy and healthy heart
- In a first, 3 cases of Delta plus variant reported in Mizoram
- Hilsa lovers rejoice as Bangladesh promises export of more fish